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Purpose: To investigate the use of pretreatment carbohydrate antigen (CA) 19-9 
and carcinoembryonic antigen (CEA) as prognostic factors to determine survival 
in pancreatic adenocarcinoma. Materials and Methods: A retrospective review of 
the medical records of patients who were diagnosed with pancreatic adenocarcino-
ma and received surgery, chemoradiotherapy or chemotherapy was performed. 
Factors, including CA 19-9 and CEA, associated with the survival of pancreatic 
cancer patients were analyzed. Results: Patients with the median age of 65 years 
were included (n=187). Elevated serum CA 19-9 levels and CEA levels were ob-
served in 75.4% and 39% of patients at diagnosis, respectively. CEA was correlat-
ed with tumor stages (p=0.005), but CA 19-9 was not. CA 19-9 and CEA were ele-
vated in 69.0% and 33.3% of patients with resectable pancreatic cancer, and 
elevated in 72.9% and 47.2% of patients with advanced pancreatic cancer, respec-
tively. The median overall survival of the normal serum CEA group was longer 
than that of the elevated serum CEA group (16.3 months vs. 10.2 months, 
p=0.004). However, the median overall survival of the normal serum CA 19-9 
group was not different from that of the elevated serum CA 19-9 group (12.4 
months vs. 13.5 months, p=0.969). The independent factors associated with over-
all survival were advanced pancreatic cancer [harzard ratio (HR) 4.33, p=0.001] 
and elevated serum CEA level (HR 1.52, p=0.032). Conclusion: Patients with ele-
vated serum CEA level at diagnosis demonstrated poor overall survival. Pretreat-
ment CEA level may predict the prognosis of patients with pancreatic adenocarci-
noma.
Key Words:   CA 19-9, carcinoembryonic antigen, pancreas adenocarcinoma, 
prognosis
INTRODUCTION
Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. 
In 2011, 44030 patients were estimated to be diagnosed with pancreatic cancer, 
with an estimated 37660 deaths due to the disease.1 Surgical resection is the only 
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MATERIALS AND METHODS
　　　
Patients and methods
We reviewed the medical records of patients diagnosed with 
pancreatic cancer at Severance Hospital (Seoul, Korea) from 
August 2007 to December 2010. All patients were histologi-
cally diagnosed with pancreatic adenocarcinoma and under-
went dynamic computed tomography (CT) of the abdomen 
and pelvis. The levels of CA 19-9 and CEA were evaluated 
before treatment. All patients received either an operation, 
chemotherapy or chemoradiotherapy (CRT), and patients 
who only received supportive care, palliative surgery or oth-
er treatments were not included in the study. The patients 
who were referred from other hospitals after receiving treat-
ment or who refused treatment were also excluded. Also, 
patients with a history of other malignancies were excluded.
The clinical variables used in this study were sex, age, 
hypertension, diabetes mellitus, Eastern Cooperative On-
cology Group (ECOG), stage, location of tumor, size of tu-
mor, albumin, total bilirubin, CA 19-9 level, CEA level and 
treatment modality. The standard diagnostic cutoff values 
for CA 19-9 and CEA were used-37 U/mL and 5 ng/mL, 
respectively. CA 19-9 and CEA were measured using che-
miluminescence immunoassay on the VITROS 3600 Im-
munodiagnostic System (Ortho-Clinical Diagnostics Inc., 
Raritan, NJ, USA) and the UniCel DxI 800 Access Immu-
noassay System (Beckman Coulter Inc., Brea, CA, USA), 
respectively. All tumors were classified as resectable pan-
creatic cancer (including stage I and II), locally advanced 
pancreatic cancer (including stage III) and advanced pan-
creatic cancer (including stage IV) using the American 
Joint Committee on Cancer (AJCC, the 7th edition) TNM 
staging system. TNM staging was based on CT scan or 
pathological results, if available. The Institutional Review 
Board approved this study for human research at Yonsei 
University College of Medicine.
Statistical analysis
Relationships between categorical variables were compared 
using χ2 test and comparisons of continuous variables in 
two groups were performed using Student’s t-test. The cor-
relations of CA 19-9 level and CEA level with tumor stages 
were evaluated using Spearman correlation. Survival in dif-
ferent subgroups was estimated by the Kaplan-Meier meth-
ods. The influence of potential prognostic factors on survival 
was assessed by multivariate analysis with the Cox propor-
curative treatment for pancreatic cancer. However, only 
5-25% of patients with pancreatic cancer are candidates for 
curative pancreatectomy.2 Most of these patients are inopera-
ble at diagnosis, and with other treatment modalities, the 
overall 5-year survival is less than 5%.3 Survival of pancre-
atic cancer patients has remained the similar since the de-
velopment of Whipple’s operation and gemcitabine. To 
provide more effective treatment to these patients, studies 
have set out to find biomarkers for better diagnosis and 
prognosis. 
Prognostic factors can predict treatment response and by 
doing so assess the risk of disease progression. In the fu-
ture, these markers may be able to guide personalized ther-
apy. So far, several tumor markers of pancreatic cancer 
have been reported. Among them, carbohydrate antigen 
(CA) 19-9 is the standard tumor marker for pancreatic can-
cer. CA 19-9 has proven to be useful in differentiating be-
nign from malignant pancreatic diseases. The sensitivity of 
CA 19-9 ranges from 41 to 86% with a specificity of 33 to 
100%.4 Carcinoembryonic antigen (CEA) is the most com-
monly used tumor marker for gastrointestinal malignancies. 
It was originally developed for pancreatic cancer and was 
used throughout 1970-1980 before the advance of CA 19-9. 
Currently, CEA is the standard tumor marker for screening 
and predicting the prognosis of colorectal cancer.5
The possibility of utilizing both markers as prognostic 
factors has been tested in several studies. Kim, et al.6 re-
ported that preoperative CA 19-9 levels could predict the 
resectability of pancreatic cancer. Also, pretreatment CA 
19-9 level was proven to be a prognostic factor in pancreat-
ic cancer treated with chemotherapy or chemoradiothera-
py.7-9 Although the usefulness for CA 19-9 as a prognostic 
marker was reported, only specific tumor stages or cases 
treated with a specific treatment modality such as opera-
tion, chemotherapy or chemoradiotherapy was included in 
these previous studies. Considering its background and use-
fulness in gastrointestinal malignancies, CEA might be also 
useful in predicting pancreatic cancer, but less is known 
about the association between pretreatment CEA level and 
the prognosis of pancreatic cancer. The potential of CA 
19-9 and CEA as prognostic factors has not been yet deter-
mined.
Thus, in this study we included patients with pancreatic 
cancer, regardless of stages and treatment modality, and an-
alyzed the factors associated with survival to determine the 
utility of pretreatment CA 19-9 and CEA in assessing the 
prognosis of patients with pancreatic adenocarcinoma.
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cated mostly at the pancreas body and tail (49.4%), but pri-
marily at the head (70%) in the normal CEA level group 
(p=0.007) (Table 3). There was no association between CA 
19-9 level and tumor stages (p=0.150), but CEA increased 
as tumor stages progressed (p=0.005). 
The comparison of survival according to serum CA 19-9 
and CEA in patients with pancreatic cancer. The median 
follow-up period of all the patients was 11.7 months (range, 
2-59.5 months). In total, 135 patients (72.2%) died by the 
time of the final analysis. The median overall survival of 
the normal serum CA 19-9 group and the elevated serum 
CA 19-9 were 12.4 months (range, 9.3-15.6 months) and 
13.5 months (12.0-15.0 months), respectively (p=0.969) 
(Fig. 1A). The median overall survival of the normal serum 
CEA group and the elevated serum CEA group were 16.1 
months (range, 12.2-19.9 months) and 10.2 months (range, 
7.5-12.9 months), respectively (p=0.005) (Fig. 1B).
Unresectable patients were analysed to compare overall 
survival and progression free survival. There were 145 pa-
tients including locally advanced pancreatic cancer and ad-
tional hazards model. Values of p<0.05 were considered 
statistically significant for all statistical analyses. Statistical 
analysis was performed using SPSS software version 17.0 
(SPSS Inc., Chicago, IL, USA).
 
RESULTS
 
Patient characteristics
One hundred and eighty-seven patients were included in 
this study, and 104 (55.6%) patients were male. The medi-
an age was 65 years (range, 31-86 years). The initial ECOG 
scores were 0 in 125 patients (66.8%) and 1-2 in 61 patients 
(32.6%). Fourty-two patients (22.5%) were classified with 
resectable pancreatic cancer, 71 patients (38%) with locally 
advanced pancreatic cancer and 74 patients (39.6%) with ad-
vanced pancreatic cancer. Tumors were primarily located at 
the pancreas head (53.5%). The median size of the tumors 
was 3.4 cm (range, 0.9-7.6 cm). Nine patients (4.8%) un-
derwent operation, 77 patients (41.2%) received chemo-
therapy and 101 patients (54%) were treated with CRT (Ta-
ble 1). The regimens of chemotherapy included gemcitabine 
only in 19 patients (24.6%), gemcitabine plus capecitabine 
in 16 patients (20.7%), gemcitabine plus cisplatin in 23 pa-
tients (30.1%) and gemcitabine plus erlotinib in 19 patients 
(24.6%). Among the patients who received CRT, 82 pa-
tients (81.1%) underwent gemcitabine based CRT and 19 
patients (18.9%) underwent 5-fluorouracil based CRT.
CA 19-9 and CEA were evaluated at initial diagnosis, 
and the median levels were 376 U/mL (range, 0.1-20000 U/
mL) and 3.4 ng/mL (range, 0.04-8566 ng/mL), respective-
ly. CA 19-9 was increased above 37 U/mL in 141 patients 
(75.4%) and CEA was increased above 5 ng/mL in 73 pa-
tients (39%).
Comparison of clinical variables according to CA 19-9 
and CEA
In the elevated CA 19-9 level group, ECOG was higher 
(87.1% vs. 12.9%, p=0.009) and total bilirubin increased 
more (2.9±4.6 g/dL vs. 1.5±2.6 g/dL, p=0.009), compared 
to the normal CA 19-9 level group (Table 2). There was no 
significant difference in the size of tumors according to CA 
19-9. In the elevated CEA level group, tumor location and 
tumor size were significantly different from the normal CEA 
level group. The sizes of tumors were larger compared to 
the normal CEA level group (3.8±1.4 cm vs. 3.2±1.0 cm, 
p=0.001). In the elevated CEA level group tumors were lo-
Table 1. Baseline Characteristics of All Patients
Characteristics No. of patients, n=187
Sex
    Male  104 (55.6%)
    Female    83 (44.4%)
Age (median)   65 (31-86)
Hypertension    61 (32.6%)
Diabetes mellitus    57 (30.5%)
ECOG
    0  125 (66.8%)
    1-2    61 (32.6%)
Stage
Resectable    42 (22.5%)
Locally advanced 71 (38%)
Advanced    74 (39.6%)
Location of tumor
    Head  100 (53.5%)
    Body    60 (32.1%)
    Tail    27 (14.4%)
Size of tumor (median) 3.4 cm (range, 0.9-7.6 cm)
Albumin (median) 4.3 g/dL (range, 2.7-5.2 g/dL)
Total bilirubin (median) 0.7 g/dL (range, 0.2-25.5 g/dL)
CA 19-9 at diagnosis 
  (median)
376 U/mL (range, 0.1-20000 U/mL)
    CA 19-9 >37 U/mL  141 (75.4%)
CEA diagnosis (median) 3.4 ng/mL (range, 0.04-8566 ng/mL)
    CEA >5 ng/mL 73 (39%)
ECOG, Eastern Cooperative Oncology Group; CA 19-9, carbohydrate anti-
gen 19-9; CEA, carcinoembryonic antigen.
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the median overall survival between the normal CEA group 
and elevated CEA group were significantly different (13.4 
months vs. 8.2 months, p=0.003). 
In unresectable patients, the median progression free sur-
vival of the normal CA 19-9 group and elevated CA 19-9 
vanced pancreatic cancer. There were 112 patients (77.2%) 
with elevated serum CA 19-9 and 59 patients (40.7%) with 
elevated CEA. The median overall survival of the normal 
CA 19-9 group and the elevated CA 19-9 group were 8.4 
months and 11.6 months, respectively (p=0.597). However, 
Table 2. Comparison of the Normal CA 19-9 Level Group and Elevated CA 19-9 Level Group
CA 19-9 (<37 U/mL) CA 19-9 (≥37 U/mL) p value*
Sex 0.842
    Male 25 (24%) 79 (76%)
    Female    21 (25.3%)    62 (74.7%)
Age (yrs) 62.3±9.4 62.9±10.0 0.720
Diabetes mellitus    13 (22.8%)    44 (77.2%) 0.706
ECOG 0.009
    0    38 (30.4%)    87 (69.6%)
    1-2      8 (12.9%)    54 (87.1%)
Tumor stages  0.150†
    Resectable 13 (31%) 29 (69%)
    LAPC    13 (18.3%)    58 (81.7%)
    Advanced 20 (27%) 54 (73%)
Location of tumor 0.891
    Head 25 (25%) 75 (75%)
    Body, tail    21 (24.1%)    66 (75.9%)
Size of tumor (cm)   3.3±1.3 3.5±1.2 0.577
Albumin (g/dL)   4.2±0.4 4.2±0.4 0.584
Total bilirubin (g/dL)   1.5±2.6 2.9±4.6 0.009
CA 19-9, carbohydrate antigen 19-9; ECOG, Eastern Cooperative Oncology Group; LAPC, locally advanced pancreatic cancer.
*χ2 test was used to compare categorical variables and Student’s t-test was used to compare continuous variables.
†Spearman correlation analysis was used.
Table 3. Comparison of the Normal CEA Level Group and Elevated CEA Level Group
CEA (<5 ng/mL) CEA (≥5 ng/mL) p value*
Sex 0.672
    Male    62 (59.6%)    42 (40.4%)
    Female    52 (62.7%)    31 (37.3%)
Age (yrs) 63.3±9.6 61.8±10.2 0.326
Diabetes mellitus    31 (54.4%)    26 (45.6%) 0.222
ECOG 0.800
    0    77 (61.6%)    48 (38.4%)
    1-2    37 (59.7%)    25 (40.3%)
Tumor stages  0.005†
    Resectable    28 (66.7%)    14 (33.3%)
    LAPC    47 (66.2%)    24 (33.8%)
    Advanced    39 (52.7%)    35 (47.3%)
Location of tumor 0.007
    Head 70 (70%) 30 (30%)
    Body, tail    44 (50.6%)    43 (49.4%)
Size of tumor (cm)   3.2±1.0 3.8±1.4 0.001
Albumin (g/dL)   4.2±0.4 4.3±0.4 0.122
Total bilirubin (g/dL)   2.7±4.0 2.4±4.6 0.732
CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; LAPC, locally advanced pancreatic cancer.
*χ2 test was used to compare categorical variables and Student’s t-test was used to compare continuous variables.
†Spearman correlation analysis was used.
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size of tumor, level of CA 19-9 and CEA were analyzed by 
univariate analysis, which showed that ECOG (1 and 2), tu-
mor stage (advanced stage), location of tumor (body & tail), 
size of tumor (>3 cm) and CEA (>5 ng/mL) were signifi-
cantly associated with poor overall survival. In multivariate 
analysis, advanced pancreatic cancer stage [compared with 
resectable, harzard ratio (HR) 4.33, confidence interval (CI) 
2.30-8.15, p=0.001] and CEA (>5 ng/mL) (HR 1.52, CI 
1.03-2.23, p=0.032) were significant prognostic factors as-
sociated with overall survival (Table 4). Subgroup analysis 
in the unresectable group showed the same result. The ad-
group were 4.6 months and 5.3 months, respectively (p= 
0.735). The median progression free survival of the normal 
CEA group and elevated CEA group were 6.3 months and 
3.7 months, respectively (p=0.012). The number of patients 
with elevated CEA level in resectable group was too small, 
the subgroup analysis was not done.
Prognostic factors affecting overall survival of the 
patients with pancreatic cancer
The association between survival and the parameters of 
sex, age, ECOG, diabetes mellitus, stage, location of tumor, 
Table 4. Univariate and Multivariate Analysis of Prognostic Factors
Variable
Univariate analysis Multivariate analysis
p value* Hazard ratio 95% CI p value*
Sex (male) 0.127 1.23 0.86-1.76 0.237
Age (>65) 0.743 0.89 0.62-1.26 0.512
ECOG 0.016
    0 1
    1 and 2 1.02 0.67-1.54 0.915
Diabetes mellitus 0.243 0.81 0.54-1.21 0.312
Tumor stages 0.001
    Resectable 1
    LAPC 1.72 0.93-3.16 0.079
    Advanced 4.33 2.30-8.15 0.001
Location of tumor
    Head 1
    Body, tail 0.013 0.94 0.64-1.39 0.780
Size of tumor (>3 cm) 0.001 1.37 0.89-2.09 0.145
CA 19-9 (>37 U/mL) 0.969 0.88 0.57-1.35 0.575
CEA (>5 ng/mL) 0.005 1.52 1.03-2.23 0.032
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; LAPC, locally advanced pancreatic cancer; CA 19-9, carbohydrate antigen 19-9; CEA, 
carcinoembryonic antigen. 
*Cox’s regression analysis was used.
Fig. 1. Overall survival. (A) Comparison of survival time between the normal CA 19-9 group and the elevated CA 19-9 group. (B) Comparison of survival time 
between the normal CEA group and the elevated CEA group. CA 19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen.
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patients received either an operation, chemotherapy, or CRT. 
In the elevated CEA level group, tumor size was larger than 
that of the normal CEA level group, and CEA level showed 
a positive correlation with tumor stages. In addition, our re-
sults showed that pretreatment CEA level was significantly 
associated with overall survival regardless of stages. In the 
unresectable group, the normal serum CEA level group 
showed longer progression free survival than the elevated 
serum CEA level group. However, the elevated CA 19-9 
was not significantly associated with poor overall survival 
and progression free survival. There might be several rea-
sons for this result. First, patients with Lewis blood type 
negative do not express the CA 19-9 antigen18 and inflam-
matory lesions of the pancreas can increase CA 19-9 level, 
even in low stages.19 Also obstructive jaundice might in-
crease the level of CA 19-9, which is an important source 
of false positive results.20,21
Association between CEA and colon cancer is well known, 
but CEA has also been reported as a prognostic marker in 
variety of other cancers such as breast cancer, cervix cancer 
and lung cancer.22-24 In our study, CEA proved to be a poten-
tial prognostic marker of pancreatic cancer, especially in 
those treated non-surgically. In the surgically treated group, 
we failed to prove the usefulness of CEA because only a 
limited number of the patients with elevated CEA had re-
sectable cancer. In the non-surgical group, CEA was not as-
sociated with the treatment response, but rather with progres-
sion free survival. This suggests that there was an acquisition 
of chemo-resistance in earlier periods and possibly different 
cancer behaviors. A few other studies showed an associa-
tion between CEA and metastasis ability. CEA is expressed 
on the cell surface and functions in cellular adhesion.25 
Therefore, malignant cells may aggravate and metastasize 
with increased CEA expressions. Recently, several cancer 
vaccines targeting CEA have been developed and they may 
improve treatment outcomes in pancreatic cancer patients 
with elevated CEA.26,27 From this point of view, pancreatic 
cancer is also a good target for cancer vaccines.
In conclusion, pretreatment elevated CEA level using the 
standard diagnostic cutoff-value contributed significant prog-
nostic information on pancreatic cancer patients. Further 
studies are needed to establish whether CEA has a predic-
tive value in regards to treatment modalities and chemo-
therapy regimens. Other potential biomarkers that could be 
useful for screening, diagnosing, and predicting treatment 
responses need to be further investigated and compared to 
CA 19-9 and CEA.
vanced cancer stage (HR 2.46, CI 1.59-3.80, p=0.001) and 
CEA (>5 ng/mL) (HR 1.61, CI 1.07-2.42, p=0.022) were 
two independent prognostic factors affecting the overall 
survival of the unresectable group. 
DISCUSSION
Pancreatic adenocarcinoma is an aggressive tumor with a 
poor prognosis. In addition, patients with pancreatic cancer 
are often diagnosed with metastatic disease or are at an in-
operable status. Even though treatment plans are devised 
based on the stage of the tumor, the patient’s condition, and 
several other clinical factors, not all patients benefit from 
conventional anti-cancer treatment. Studies have evaluated 
the efficacy of various tumor markers for improved predic-
tion of treatment responses, risk of cancer progression, and 
medical costs in pancreatic cancer. The most widely used 
tumor markers for pancreatic cancer are CA 19-9 and CEA. 
CA 19-9 was first isolated from a colorectal cell line and 
has since become the most widely used biomarker for pan-
creatic cancer.10 Although CA 19-9 is not suitable as a 
screening marker in asymptomatic patients, it is useful for 
differentiating benign disease from malignant pancreatic 
disease. Also, a few studies reported that preoperative CA 
19-9 was correlated with resectability and prognosis after 
surgery.11,12 In addition, postoperative CA 19-9 can predict 
overall survival and disease-free survival after pancreatic 
cancer resection and adjuvant chemotherapy.13 CEA was 
found more than 45 years ago and has been primarily used 
to monitor colorectal cancer.14 CEA has also been used in 
pancreatic cancer, but its sensitivity and specificity are too 
low to be used as a diagnostic biomarker. Instead, a preoper-
ative combination of CEA and CA 19-9 has been used to 
predict the resectability of pancreatic cancer.6,12,15 Moreover, 
a few studies suggested that pretreatment CEA was associat-
ed with poor treatment outcomes.16,17 However, these studies 
included a small number of patients, a specific tumor stage, 
a specific treatment modality, or applied a wide range of cut-
off values. To determine whether CA 19-9 and CEA can be 
generally applicable prognostic markers of pancreatic can-
cer, the use of these biomarkers should be tested in a large 
number of patients with various stages of pancreatic cancer.
In this study, we analyzed 187 patients diagnosed with 
pancreatic adenocarcinoma. Cancers of stage 1 to 4 accord-
ing to AJCC staging were all included and the standard di-
agnostic cutoff values of CA 19-9 and CEA were used. All 
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